NSE-listed companies offering contract development and manufacturing (CDMO) services or active pharmaceutical ingredient (API) production, positioned to benefit from global supply chain diversification away from China.
Sectors represented: Healthcare
RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. . Risingshareofbiologicsalongwithincreasinginvestmentsin ent. . RapidmomentuminspecializedCDMOservicestosupportever. increasingclinicaltrials,e.g.,HighpotencyAPIswithstringent. exposurecontrolrequirements. .
Pharmaceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years. aceutical Exports. India’s formulation exports are expected to grow at a. CAGR of 6-8% from fiscal 2023 to fiscal 2025, as against. the growth rate of 8-9% over the previous five years.
Robust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business. 17 obust regulatory filings to strengthen the base for growth in the formulation segment. Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and SFDA, Saudi Arabia. 16. CDMO Business...
DCGI approvals. 1. , along with. 923 FSSAI approvals. 150. 4. 925+. 3. (1) As of 31st March 2024; (2) As of 1st Aug 2024. Domestic Branded Formulations. 59. th. Rank in Indian Branded. Formulations. 1. 140. Brands. 69%. Chronic and. sub-chronic segment. 1. 1.5k+. Salesforce. Exports Oriented Branded Formulations. 179. 246. 134. 289. Mar’22Mar’23Mar’24. Under Registration. Dossiers.
Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3. 5.0. 5.6. 6.2. 7.1. 8.2. 9.5. 10.8 920242029F. Drug Product (Formulation)Drug Substance (API)Total. 92. 95. 106. 113. 120. 129. 139. 150. 162. 176. 190. 2019202020212022202320242025F2026F2027F2028F2029F. 3.1. 3.4. 3.8. 4.3.
Steroidsproducts. ❏HPAPIsdevelopmentandmanufacturing. ❏USFDAapprovedmanufacturingfacilityfor. upcomingAPIs. ❏Flowchemistryfromlabtomanufacturing. ❏CompleteCMCdocumentationsupport. Xanthine derivatives & Intermediates. (Caffeine and others). ❏LargestIndianManufacturerforXanthine cturingfacilityfor. upcomingAPIs. ❏Flowchemistryfromlabtomanufacturing. ❏CompleteCMCdocumentationsupport.
This quality upgrade. cycle, though challenging for. smaller units, is fundamentally. strengthening India's credibility. as a globally trusted, regulation-. compliant API supplier a critical. competitive advantage as. regulated market buyers tighten. supplier qualification standards. 7.74%. CAGR. 14.2. 2025. 15.3. 2026. 22.3. 2031. Growth by Market Segment.
Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as. formulations Analytical Development. . Pre-GMP Scale-up. Formulation Development. . Pre-Formulation Studies. . Analytical Development. Ability to manufacture across a. wide range of scale in API as well as.
Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg. ACITIES. CLOSE PROXIMITY. TO CLIENTS WITH. GLOBAL PRESENCE. Integrated CDMO Player present along the entire value chain from building blocks to commercialization and product launch stage. Large Scale Mfg.
Transplant & Immuno. Isacrest. TM. 18. Trusted CDMO partner for Fermentation & Semi-Synthetic API’s. CDMO Overview. Provide contract research and manufacturing. services for developing APIs and formulations. Prioritizes innovation, backed by a DSIR-. certified R&D facility with a team of 180+ tic API’s. CDMO Overview. Provide contract research and manufacturing.
Process DevelopmentQuality & Regulatory ServicesDrug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced. contamination risk and higher uptime. . Clinical batches to high-speed commercial. lines inc. ug Substance Drug Product. . Mammalian and microbial platforms. . Single-use bioreactors for lower cost, reduced.
Solutions (CMS)/ Contract. Development and. Manufacturing. Organization (CDMO). Develop and manufacture pharmaceutical ingredients and. intermediates in line with customer expectations. Development Molecules utions (CMS)/ Contract. Development and. Manufacturing. Organization (CDMO). Develop and manufacture pharmaceutical ingredients and. intermediates in line with customer expectations.